NAPSR News: Mylan Acquires U.S. Rights to Arixtra Injection From Aspen Global

WASHINGTON - Sept. 10, 2014 - PRLog -- Mylan Ireland Limited has acquired the US commercialization, marketing and intellectual property rights for Arixtra® (fondaparinux sodium) Injection and the authorized generic (AG) of Arixtra from Aspen Global Incorporated. Arixtra is intended to treat prophylaxis of deep vein thrombosis (DVT). DVT  may lead to pulmonary embolism (PE) in patients undergoing hip fracture surgery. This also includes thromboembolic complications that may arise from, hip replacement surgery, knee replacement surgery or abdominal surgery.

Mylan currently markets Arixtra in the U.S. through an interim distribution arrangement with Aspen. Apotex presently sells AG of Arixtra which will transition over the Mylan Institutional by the end of the year.

Mylan CEO Heather Bresch stated, "DVT/PE is a serious health concern that is estimated to affect up to 600,000 people in the U.S.1 The addition of Arixtra is an attractive opportunity to broaden the range of therapeutic categories we market in the U.S., in both the hospital and retail settings, and bolster our growing portfolio of complex injectables to better meet our customers' needs."

In accordance with the acquisition Mylan will pay Aspen $225 million and an additional $75 million will be held in escrow and released upon satisfaction of certain conditions. According the terms and conditions, Aspen will supply Arixtra and the AG of Arixtra to Mylan, all other terms of the agreement is confidential and the transaction is subject to regulatory approval.

The acquisition of Arixtra will be a valuable boon to Mylan’s expanded portfolio. According to IMS health, Arixtra and the AG of Arixtra had U.S. sales of approximately $18.8 million and $95.3 million, respectively, for the 12 months ending June 30, 2014.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/